Corline Biomedical (CLBIO) Q4 2024 earnings summary

Executive summary

• Strategic shift prioritized medical device business and investments in production and quality systems to support upcoming US launch of CHSTM, targeting the fast-growing PFA segment for cardiac arrhythmia treatments.

• Globe® catheter, coated with CHSTM, submitted for FDA approval by Kardium in December 2024; strong clinical results and safety profile position it well in a rapidly expanding market.

• Focus on early-stage licensing of CHSTM technology to multiple customers, especially in the US, with about 10 customers in evaluation phase.

• Renaparin® continues to be evaluated in regenerative medicine and kidney transplantation, with positive safety and efficacy signals from phase 1 study.

• Strategic deprioritization and non-cash write-down of Cytoparin™ development to focus resources on medical device segment.

Financial highlights

• Q4 2024 net sales: 2,012 KSEK (6,244 KSEK Q4 2023); full-year 2024 net sales: 9,775 KSEK (25,030 KSEK 2023).

• Q4 2024 result after financial items: -14,161 KSEK (-600 KSEK Q4 2023); full-year: -23,194 KSEK (-1,809 KSEK 2023).

• One-time write-down of intangible assets: -9,992 KSEK in Q4 and full-year 2024.

• Q4 2024 EPS: -0.62 SEK (-0.03 Q4 2023); full-year 2024 EPS: -1.06 SEK (-0.08 2023).

• Cash and cash equivalents at year-end: 17.7 MSEK (17.0 MSEK 2023); equity ratio: 92% (93% 2023).

Outlook and guidance

• 2025 expected to mark the start of a growth journey, with focus on US market launch and expansion of CHSTM applications.

• Cost structure adjusted to support new strategy and target profitability by end of 2025.

• Cash and expected sales from current contracts projected to cover operational needs for at least 12 months.